Skip to main content
. 2021 Aug 31;14:3509–3518. doi: 10.2147/IDR.S325520

Figure 1.

Figure 1

Effect of relebactam on MIC distribution of imipenem against: (A) P. aeruginosa isolates (n = 1886); (B) imipenem-non-susceptible P. aeruginosa (n = 835); (C) MDR P. aeruginosa isolates (n = 835). Dashed line represents the FDA identified susceptibility breakpoint of imipenem/relebactam of ≤ 2 mg/mL for P. aeruginosa.

Abbreviations: MIC, minimum inhibitory concentrations; MDR, multidrug resistance.